DelveInsight's Interleukin-13 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report ...

On 03 September 2025, Hoffmann-La Roche conducted a study is to assess the long-term safety and to explore the efficacy of ...

The time to onset of action was fastest with IL-17 inhibitors, followed by IL-23, IL-12/23, then PDE-4 and JAK inhibitors for ...

Extended treatment with benralizumab led to durable remission, reduced OGC burden, sustained eosinophil depletion, and low relapse rates in patients with EGPA.

Individuals with Crohn disease and comorbid type 2 diabetes have more unfavorable clinical outcomes and are less likely to ...

A newly developed molecule brings together two powerful immunotherapy strategies in one treatment. Researchers at the University of Basel and University Hospital Basel, Switzerland, have demonstrated ...

Following the Mediterranean diet reduces your risk of gum disease, which reduces your risk for inflammation that leads to ...

Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor 1 Filing ...

Following the Mediterranean diet reduces your risk of gum disease, which reduces your risk for inflammation that leads to ...

Clinical results were spottier. Chen and colleagues tracked SLE Disease Activity Index (SLEDAI) values from pretreatment baseline through 3 months. The first patient, who got just one 2-mg dose, ...

May 23, 2025 -- The FDA has approved the asthma drug Nucala for adults with chronic obstructive pulmonary disease (COPD). It is the second biologic therapy approved for the condition, following the ...